IP Verse

Galenicum Health S.l. Analysis

LAW FIRM ANALYSIS

Latest European patent oppositions filed by Galenicum Health S.l.

Patent:
EP3634463
Title:
Improved Protocol For Treatment Of Lupus Nephritis
Applicant:
AURINIA PHARMACEUTICALS INC.
Opposition Date:
2024-06-27
Patent:
EP2508188
Title:
Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate
Applicant:
BRISTOL-MYERS SQUIBB COMPANY
Opposition Date:
2024-02-09
Patent:
EP2482812
Title:
Therapeutic Uses Of Pharmaceutical Compositions
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Opposition Date:
2023-10-11
Patent:
EP2797581
Title:
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione
Applicant:
AMGEN (EUROPE) GMBH
Opposition Date:
2021-02-08
Patent:
EP2139494
Title:
Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate
Applicant:
BRISTOL-MYERS SQUIBB COMPANY
Opposition Date:
2020-12-11
Patent:
EP3326620
Title:
Solid Compositions Comprising A Glp-1 Agonist And A Salt Of N-(8-(2- Hydroxybenzoyl)Amino)Caprylic Acid
Applicant:
NOVO NORDISK A/S
Opposition Date:
2020-12-04
Patent:
EP3302565
Title:
Solid Dosage Forms Of Palbociclib
Applicant:
PFIZER INC.
Opposition Date:
2020-08-05
Patent:
EP3300721
Title:
Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Applicant:
NOVO NORDISK A/S
Opposition Date:
2019-12-04
Patent:
EP2962690
Title:
(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Applicant:
AMGEN (EUROPE) GMBH
Opposition Date:
2019-10-16
Patent:
EP2827845
Title:
Compositions Comprising A Delivery Agent And Preparation Thereof
Applicant:
NOVO NORDISK A/S
Opposition Date:
2019-09-26

Top clients of Galenicum Health S.l. filing patent oppositions

Company:
GALENICUM HEALTH S.L.U.
Count:
10
Company:
GALENICUM
Count:
1